For the quarter ending 2025-09-30, SILO made $18,025 in revenue. -$1,108,657 in net income. Net profit margin of -6150.66%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | |
|---|---|---|---|---|
| License fee revenue | 18,025 | - | 18,025.5 | |
| Cost of revenues | 20,687 | - | 1,459.5 | |
| Gross profit (loss) | -2,662 | - | 16,566 | |
| Compensation expense | 227,132 | - | 226,693.25 | |
| Professional fees | 313,194 | - | 299,686.25 | |
| Research and development | 543,615 | - | 592,039 | |
| Other selling, general and administrative expenses | 64,863 | - | 74,571 | |
| Total operating expenses | 1,148,804 | - | 1,192,989.5 | |
| Loss from operations | -1,151,466 | - | -1,176,423.5 | |
| Net realized loss on short-term debt investments | - | - | -256.25 | |
| Interest and dividend income, net | 44,604 | - | 83,291.25 | |
| Interest expense | 886 | - | 1,271 | |
| Foreign currency transaction loss | - | - | -3,560.5 | |
| Unrealized loss on crypto assets | 2,690 | - | - | |
| Provision for income taxes | - | 0 | 0 | |
| Total other income, net | 41,028 | - | 78,203.5 | |
| Loss before provision for income taxes | -1,110,438 | -1,204,293 | -1,098,220 | |
| Net loss | -1,110,438 | -1,204,293 | -1,098,220 | |
| Unrealized gain on short-term debt investments | 1,781 | -1,140 | 2,161.5 | |
| Total comprehensive loss | -1,108,657 | -1,205,433 | -1,096,058.5 | |
| Basic (in dollars per share) | -0.12 | -0.19 | -0.298 | |
| Basic (in shares) | 9,331,346 | 6,279,733 | 920,097.25 | |
| Diluted (in dollars per share) | -0.12 | -0.19 | -0.298 | |
| Diluted (in shares) | 9,331,346 | 6,279,733 | 920,097.25 | |
Silo Pharma, Inc. (SILO)
Silo Pharma, Inc. (SILO)